Palupiprant

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.

**Synonyms:** - AN 0025 - AN-0025 - AN0025 - E 7046 - E-7046 - E7046 - EP4 Antagonist E7046 - EP4 Inhibitor E7046 - ER-886046 - PALUPIPRANT - Prostaglandin E EP4 Receptor Antagonist E7046 - Prostaglandin E2 EP4 Receptor Inhibitor AN0025